Supplementary protection
LT - 3'-(2Z)-1-(3,4-Dimetilfenil)-1,5-dihidro-3-metil-5-okso-4H-pirazol-4-ilidenhidrazino-2'-hidroksi-1,1'-bifenil-3-karboksirūgšties bis-(monoetanolaminas)
EN - 3`- (2Z)- 1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE HYDRAZINO -2`-HYDROXY- 1,1`-BIPHENYL -3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE)
SPC
| (11) |
Number of the document |
C 1534390 |
| (68) |
Number of the document |
1534390
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2010 007 |
| (22) |
Date of filing the application |
2010-05-10 |
| (41) |
Date of publication of the application |
2010-06-28 |
|
Date of publication of SPC |
2010-12-27 |
| (24) |
Date of coming into effect of SPC |
2023-05-22 |
Applicant
| (71) |
GlaxoSmithKline LLC,
One Franklin Plaza P.O. Box 7929, Philadelphia, PA 19101,
US
|
Grantee
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
Attorney or representative
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/10/612/001, 2010-03-11 EU/1/10/612/002, 2010-03-11 EU/1/10/612/003, 2010-03-11 EU/1/10/612/004, 2010-03-11 EU/1/10/612/005, 2010-03-11 EU/1/10/612/006, 2010-03-11
|
Calculated date of expiry of the SPC
| (94) |
2025-03-15 |
Name of the product protected by the basic patent
| (95) |
Eltrombopago olaminas |
Paediatric extension
|
Request filed |
SPC extension granted until |
Request refused |
|
2019-10-11 |
2025-09-15 |
|
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-04-22 |
|
347.00
EUR
|
